The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of datopotamab deruxtecan (Dato-DXd) in patients with hormone receptor-positive/HER2-negative metastatic breast cancer.
More Breast Cancer Treatment Guidelines
